Omrix
Portfolio companies
Omrix Biopharmaceuticals was a marketing stage biotechnology company that developed and marketed Quixil, a novel biodegradable human plasma derived protein used as haemostat to control blood losses in surgery, as well as a suite of biological immunological drugs – specialized IVIGs.
The Quixil, Omrix’s leading product, became the first human plasma based surgical sealant to be licensed in the United Kingdom in 1999 and received FDA approval in the U.S. in 2003. In April 2006, Omrix successfully completed its IPO on the NASDAQ and in 2008, was acquired by Johnson & Johnson.